Accessibility: Skip TopNav
Figure 1
Refractory Patients’ Serum IgM Levels After Treatment with Mavorixafor + Ibrutinib vs. Ibrutinib Monotherapy With or Without CXCR4 Mutations
Format
PNG
Source
X4 Pharmaceuticals
Downloads
Original
Large
Medium
Small